March 2016March 2016
New Product - Entresto
Entresto (sacubitril/valsartan) exhibits the novel mechanism of action of an angiotensin receptor neprilysin inhibitor (ARNI) by simultaneously inhibiting neprilysin (neutral endopeptidase; NEP) via LBQ657, the active metabolite of the prodrug sacubitril, and by blocking the angiotensin II type-1 (AT1) receptor via valsartan. The complementary cardiovascular benefits and renal effects of Entresto in heart failure patients are attributed to the enhancement of peptides that are degraded by neprilysin, such as natriuretic peptides (NP), by LBQ657 and the simultaneous inhibition of the deleterious effects of angiotensin II by valsartan. Entresto is indicated in adults for the treatment of chronic heart failure (NYHA class II-IV) with reduced ejection fraction. Entresto is contraindicated in the following circumstances. Concomitant use with ACE inhibitors, known history of angioedema related to previous ACE inhibitor or angiotensin receptor blocker (ARB) therapy, hereditary or idiopathic angioedema, concomitant use with aliskiren in patients with type 2 diabetes, severe hepatic impairment, biliary cirrhosis and cholestasis, and pregnancy. Entresto is available as 24/26 tablets (containing 24.3 mg of sacubitril and 25.7 mg of valsartan); Entresto 49/51 (containing 48.6 mg of sacubitril and 51.4 mg of valsartan); and Entresto 97/103 (containing 97.3 mg of sacubitril and 102.8 mg of valsartan) in packs of 56’s.
Copyright © MIMS Australia Pty Ltd. All rights reserved.
MIMS Australia
Level 2, 1 Chandos Street
St Leonards NSW 2065
Phone: 1800 800 629
info@mims.com.au
www.mims.com.au